|
DYN | Dyne Therapeutics, Inc. |
|
|
DYN | Dyne Therapeutics, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.41 |
| Leverage | 20.22% |
| Market Cap | $ 1.7B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -422.7m |
| Margin | -1670.20% |
Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases in the United States. The company is headquartered in Waltham, Massachusetts.